

KOPRAN LIMITED							
AUDITED FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED 31st MARCH, 2013							
Part - I (Rupees in lakhs)							
Particulars	Standalone				Consolidated		
	Quarter ended			Year ended		Year ended	
	31/03/2013	31/12/2012	31/03/2012	31/03/2013	31/03/2012	31/03/2013	31/03/2012
	Audited	Unaudited	Unaudited	Audited	Audited	Audited	Audited
Net Sales / Income from Operations	7455	5627	5,392	24,330	19,245	24,330	19,244
Other Operating Income	219	148	166	692	646	692	646
<b>Total Income from operations</b>	<b>7674</b>	<b>5775</b>	<b>5558</b>	<b>25022</b>	<b>19891</b>	<b>25022</b>	<b>19890</b>
Expenditure							
Changes in Inventories of Finished Goods, Work-in- Progress and stocks- in-trade	300	(309)	(89)	(408)	698	(408)	698
Cost of Materials Consumed	4568	3,813	3,565	15,823	11,946	15,827	11,950
Purchase of Stock- in - trade	0	-	8	-	43	-	43
Employee Benefits Expenses	643	536	426	2,048	1,752	2,103	1,798
Depreciation	305	305	292	1,208	1,142	1,246	1,180
Other Expenses	1140	1,038	861	4,129	3,283	4,133	3,287
<b>Total Expenses</b>	<b>6956</b>	<b>5,383</b>	<b>5,063</b>	<b>22,800</b>	<b>18,864</b>	<b>22,901</b>	<b>18,956</b>
<b>Profit (Loss) from operations before other income, interest and exceptional items</b>	<b>718</b>	<b>392</b>	<b>495</b>	<b>2,222</b>	<b>1,027</b>	<b>2,121</b>	<b>934</b>
Other Income	39	118	1	172	556	181	566
<b>Profit (Loss) before interest and exceptional items</b>	<b>757</b>	<b>510</b>	<b>496</b>	<b>2,394</b>	<b>1,583</b>	<b>2,302</b>	<b>1,500</b>
Finance Cost	351	284	186	1,188	966	1,188	966
<b>Profit (Loss) before exceptional items</b>	<b>406</b>	<b>226</b>	<b>310</b>	<b>1,206</b>	<b>617</b>	<b>1,114</b>	<b>534</b>
Exceptional items	-	-	-	-	-	-	-
<b>Profit (Loss) before tax</b>	<b>406</b>	<b>226</b>	<b>310</b>	<b>1,206</b>	<b>617</b>	<b>1,114</b>	<b>534</b>
Less :Tax expenses	-	-	-	-	-	-	-
<b>Net Profit for the period</b>	<b>406</b>	<b>226</b>	<b>310</b>	<b>1,206</b>	<b>617</b>	<b>1,114</b>	<b>534</b>
Paid up equity share Capital (Face value Rs 10/-)	3,905	3,905	3,905	3,905	3,905	3,905	3,905
Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	8,048	6,842	4,958	3,839
<b>Earning Per Share (EPS) before and after Exceptional Item</b>							
a) Basic	1.04	0.58	0.79	3.09	1.58	2.85	1.37
b) Diluted	1.04	0.58	0.79	3.09	1.58	2.85	1.37
<b>Part II</b>							
<b>(A) PARTICULARS OF SHAREHOLDING</b>							
Public shareholding							
Number of shares	25510073	25809523	25809523	25510073	25809523	25510073	25809523
Percentage of shareholding	65.33%	66.09%	66.09%	65.33%	66.09%	65.33%	66.09%
Promoters and Promoter Group Shareholding							
a) Pledged / Encumbered							
Number of shares	1852500	552500	552500	1852500	552500	1852500	552500
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	13.68%	4.17%	4.17%	13.68%	4.17%	13.68%	4.17%
Percentage of shares (as a % of the total share capital of the company)	4.74%	1.42%	1.42%	4.74%	1.42%	4.74%	1.42%
b) Non - encumbered							
Number of shares	11686903	12687453	12687453	11686903	12687453	11686903	12687453
Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	86.32%	95.83%	95.83%	86.32%	95.83%	86.32%	95.83%
Percentage of shares (as a % of the total share capital of the company)	29.93%	32.49%	32.49%	29.93%	32.49%	29.93%	32.49%
<b>(B) INVESTOR COMPLAINTS</b>							
				3 Months ended 31-03-2013			
Pending at the beginning of the quarter				-			
Received during the quarter				1			
Disposed off during the quarter				1			
Remaining unresolved at the end of the quarter				-			
<b>Notes:-</b>							
(1) The above results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on 29th May, 2013							
(2) The Company is engaged primarily in Pharmaceuticals business and there are no separate reportable segments as per AS-17.							
(3) The figures for the quarter ended 31st March, 2013 are the balancing figures between audited figures in respect of full financial year ended 31st March, 2013 and the unaudited published year to date figures upto the 3rd quarter ended 31st December, 2012.							
(4) <b>Auditors observation:</b>							
a) Investments and Advances made to Subsidiary Company, Kopran Research Laboratories Ltd (KRLL) as at 31-03-2013 amounting to Rs. 5232.56 Lacs, (as at 31-03-2012 Rs. 5182.66 Lacs) are in the opinion of the Auditors doubtful of realisation. In the opinion of the Management, no provision is required to be made because the investment in the Subsidiary Company, KRLL, is long term, for strategic reasons.							
(5) Other Income includes net exchange Loss of Rs.33.24 lacs (previous year Gain of Rs.269.29 lacs) and interest of Rs.179.63 lacs (previous year Rs.231.67 lacs)							
(6) Figures for the previous accounting period have been regrouped wherever necessary.							




(7) Statement of Assets and Liabilities as at 31st March, 2013.

(Rupees in lakhs)

Particulars	Standalone		Consolidated	
	As at year 31-03-2013	As at year 31-03-2012	As at year 31-03-2013	As at year 31-03-2012
	Audited	Audited	Audited	Audited
<b>I. EQUITY AND LIABILITIES</b>				
<b>1. Shareholders Funds</b>				
(a) Share Capital	4763	4763	4763	4763
(b) Reserves and Surplus	8048	6842	4959	3839
<b>Total</b>	<b>12811</b>	<b>11605</b>	<b>9722</b>	<b>8602</b>
<b>2. Non-current liabilities</b>				
(a) Long-term borrowings	6948	6459	6948	6459
(b) Other Long-term liabilities			25	25
(c) Long-term provisions	357	313	360	316
<b>Total</b>	<b>7305</b>	<b>6772</b>	<b>7333</b>	<b>6800</b>
<b>3. Current liabilities</b>				
(a) Short-term borrowings	2437	3113	2491	3165
(b) Trade payables	4684	4171	4698	4182
(c) Other current liabilities	2056	2269	2074	2285
(d) Short-term provisions	12	11	12	12
<b>Total</b>	<b>9189</b>	<b>9564</b>	<b>9275</b>	<b>9644</b>
<b>TOTAL</b>	<b>29305</b>	<b>27941</b>	<b>26330</b>	<b>25046</b>
<b>II. ASSETS</b>				
<b>1. Non-current assets</b>				
(a) Fixed Assets				
(i) Tangible assets	10618	11160	10850	11431
(ii) Intangible assets			1	1
(iii) Capital work-in-progress	93	-	1985	1892
(b) Non-current investment	687	687	81	81
(c) Long-term loans and advances	5597	5431	1152	986
<b>Total</b>	<b>16995</b>	<b>17278</b>	<b>14069</b>	<b>14391</b>
<b>2. Current assets</b>				
(a) Inventories	3674	3515	3674	3515
(b) Trade receivables	4961	3752	5118	3901
(c) Cash and Bank balances	363	952	379	966
(d) Short-term loans and advances	3312	2444	3090	2273
<b>Total</b>	<b>12310</b>	<b>10663</b>	<b>12261</b>	<b>10655</b>
<b>TOTAL</b>	<b>29305</b>	<b>27941</b>	<b>26330</b>	<b>25046</b>

KOPRAN LIMITED

  
Surendra Somani  
Executive Vice Chairman

Place : Mumbai  
Date : 29-05-2013

